Qvin’s Q-Pad is a clinically validated, FDA-listed menstrual pad embedded with dried blood spot (DBS) technology, designed to passively collect menstrual blood (MB) as a non-invasive, self-administered alternative to traditional diagnostic methods. MB is uniquely reflective of the endometrial environment, containing a mixture of whole blood, endometrial cells, immune mediators, cytokines, and a diverse proteomic and lipidomic profile that mirrors intrauterine biology. Studies have shown that MB from individuals with endometriosis exhibits distinct molecular signatures, including elevated expression of estrogen-regulating genes (aromatase, SF-1, HSD17B2) [1], altered lipid profiles [2], and upregulation of inflammatory proteins like CXCL5 and IL1RN [3]. Sensory nerve fibers linked to endometriosis-associated pain have also been identified in eutopic endometrium, further supporting the biological specificity of MB [4]. Importantly, MB contains over 350 proteins not found in peripheral blood or vaginal secretions [5], offering a unique window into reproductive health. Diagnostic delays—particularly among adolescents and young women with dysmenorrhea—highlight the unmet need for early, non-invasive tools [6]. By enabling stabilized, lab-compatible MB collection at home, the Q-Pad offers a scalable solution for endometriosis detection, with studies demonstrating high sensitivity and specificity using Q-Pad-derived transcriptomic and proteomic profiles [1–3]. Compared to invasive procedures or venipuncture, the Q-Pad improves access, compliance, and sample integrity—positioning it as a transformative platform for menstrual blood diagnostics.